Clinical Trials Directory

Trials / Conditions / Human Immunodeficiency Virus Type 1

Human Immunodeficiency Virus Type 1

13 registered clinical trials studyying Human Immunodeficiency Virus Type 1.

StatusTrialSponsorPhase
WithdrawnMK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Inf
NCT05700734
Merck Sharp & Dohme LLCPhase 1
CompletedA Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy
NCT05261191
MacroGenicsPhase 1
TerminatedOral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)
NCT04644029
Merck Sharp & Dohme LLCPhase 3
CompletedA Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspensi
NCT02547870
Janssen Infectious Diseases BVBAPhase 1
Active Not RecruitingA Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who P
NCT02494986
Janssen Sciences Ireland UCPhase 2
CompletedStudy to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF)
NCT02269917
Janssen R&D IrelandPhase 3
WithdrawnA Study to Assess the Safety and Effectiveness of Darunavir for Treating Human Immunodeficiency Virus-Type I (
NCT01726348
Janssen Pharmaceutica—
CompletedA Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive H
NCT00838162
Tibotec Pharmaceuticals, IrelandPhase 2
WithdrawnMaraviroc Compassionate Use
NCT00719823
ViiV HealthcarePhase 3
CompletedTMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combina
NCT00540449
Tibotec Pharmaceuticals, IrelandPhase 3
CompletedA Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV
NCT00524368
Tibotec Pharmaceuticals, IrelandPhase 3
CompletedA Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC1
NCT00128830
Tibotec Pharmaceuticals, IrelandPhase 2
CompletedA Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretro
NCT00110305
Tibotec Pharmaceuticals, IrelandPhase 2